Increased proliferation is associated with CNS invasion in meningiomas.
Brain invasion
CNS invasion
Ki67
MIB1
Meningioma
Proliferation
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
24
09
2021
accepted:
30
10
2021
pubmed:
21
11
2021
medline:
3
3
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Meningiomas are the most common benign intracranial neoplasms. CNS invasion in meningiomas has been integrated into the 2016 WHO classification of CNS tumors as a stand-alone criterion for atypia. Since then, its prognostic impact has been debated based on contradictory results from retrospective analyses. The aim of the study was to elucidate whether histopathological evidence of CNS invasion is associated with increased proliferative potential. We have conducted a quantified measurement of the proliferation marker Ki67 and analyzed its association with CNS invasion determined by histology together with other established prognostic markers of progression. Routine, immunohistochemical staining for Ki67 were digitalized and automatic quantification was done using Image J software. Overall, 1718 meningiomas were assessed. Histopathological CNS invasion was seen in 108 cases (6.7%). Uni- and multivariate analysis revealed a significantly higher Ki67 proliferation rate in meningiomas with CNS invasion (p < 0.0001 and p = 0.0098, respectively). Meningiomas with histopathological CNS invasion show a higher proliferative activity.
Identifiants
pubmed: 34800210
doi: 10.1007/s11060-021-03892-7
pii: 10.1007/s11060-021-03892-7
pmc: PMC8651603
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-254Informations de copyright
© 2021. The Author(s).
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer. 2002 Apr 15;94(8):2151-9
pubmed: 12001111
Neuropathol Appl Neurobiol. 2021 Oct;47(6):724-735
pubmed: 33508895
J Neurooncol. 2021 Sep;154(2):237-246
pubmed: 34350560
Am J Surg Pathol. 1997 Dec;21(12):1455-65
pubmed: 9414189
Nat Commun. 2017 Feb 14;8:14433
pubmed: 28195122
Cancers (Basel). 2021 Jun 29;13(13):
pubmed: 34209798
Cancers (Basel). 2021 Jul 20;13(14):
pubmed: 34298854
Cancer. 1998 Jun 1;82(11):2262-9
pubmed: 9610708
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Surg Pathol. 2020 May;28(3):273-279
pubmed: 31771372
Neuro Oncol. 2016 Apr;18(4):565-74
pubmed: 26493095
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287241
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Brain Tumor Pathol. 2021 Apr;38(2):81-95
pubmed: 33403457
Neuro Oncol. 2017 Oct 1;19(10):1298-1307
pubmed: 28419308
Neuro Oncol. 2021 Aug 2;23(8):1273-1281
pubmed: 33367841
Acta Neuropathol. 2016 Sep;132(3):479-81
pubmed: 27464983
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Front Oncol. 2020 Aug 28;10:1522
pubmed: 32983999
J Cell Biol. 2005 Oct 24;171(2):361-71
pubmed: 16247032
World Neurosurg. 2011 Dec;76(6):564-71
pubmed: 22251505
Clin Neuropathol. 2020 Nov/Dec;39(6):256-262
pubmed: 32831157
J Neurooncol. 2019 Dec;145(3):469-477
pubmed: 31713016